Disulfiram for the treatment of cocaine dependence
Background Cocaine is a psychostimulant used by approximately 0.4% of the general population worldwide. Cocaine dependence is a chronic mental disorder characterised by the inability to control cocaine use and a host of severe medical and psychosocial complications. There is current no approved phar...
Gespeichert in:
Veröffentlicht in: | Cochrane database of systematic reviews 2024-01, Vol.2024 (1), p.CD007024-CD007024 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Cocaine is a psychostimulant used by approximately 0.4% of the general population worldwide. Cocaine dependence is a chronic mental disorder characterised by the inability to control cocaine use and a host of severe medical and psychosocial complications. There is current no approved pharmacological treatment for cocaine dependence. Some researchers have proposed disulfiram, a medication approved to treat alcohol use disorder.
This is an update of a Cochrane review first published in 2010.
Objectives
To evaluate the efficacy and safety of disulfiram for the treatment of cocaine dependence.
Search methods
We updated our searches of the following databases to August 2022: the Cochrane Drugs and Alcohol Group Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL, and PsycINFO. We also searched for ongoing and unpublished studies via two trials registries. We handsearched the references of topic‐related systematic reviews and included studies. The searches had no language restrictions.
Selection criteria
We included randomised controlled trials that evaluated disulfiram alone or associated with psychosocial interventions versus placebo, no intervention, other pharmacological interventions, or any psychosocial intervention for the treatment of cocaine dependence.
Data collection and analysis
We used standard methodological procedures expected by Cochrane.
Main results
Thirteen studies (1191 participants) met our inclusion criteria.
Disulfiram versus placebo or no treatment
Disulfiram compared to placebo may increase the number of people who are abstinent at the end of treatment (point abstinence; risk ratio (RR) 1.58, 95% confidence interval (CI) 1.05 to 2.36; 3 datasets, 142 participants; low‐certainty evidence). However, compared to placebo or no pharmacological treatment, disulfiram may have little or no effect on frequency of cocaine use (standardised mean difference (SMD) −0.11 standard deviations (SDs), 95% CI −0.39 to 0.17; 13 datasets, 818 participants), amount of cocaine use (SMD −0.00 SDs, 95% CI −0.30 to 0.30; 7 datasets, 376 participants), continuous abstinence (RR 1.23, 95% CI 0.80 to 1.91; 6 datasets, 386 participants), and dropout for any reason (RR 1.20, 95% CI 0.92 to 1.55; 14 datasets, 841 participants). The certainty of the evidence was low for all these outcomes. We are unsure about the effects of disulfiram versus placebo on dropout due to adverse events (RR 12.97, 95% CI 0.77 to 218.37; 1 study, 67 participants) and on the occu |
---|---|
ISSN: | 1465-1858 1465-1858 1469-493X |
DOI: | 10.1002/14651858.CD007024.pub3 |